About this trial
This study is designed to evaluate whether the addition of nasopharyngeal lymphoid tissue ablation to full-house endoscopic sinus surgery (ESS) provides superior control of nasal mucosa inflammation compared to full-house ESS alone in patients with nasal polyps. Thirty-two adult participants will be randomly assigned to undergo either full-house ESS only or full-house ESS combined with nasopharyngeal lymphoid tissue ablation. The primary outcome will be assessed through changes in inflammatory cell profiles at 1, 3, and 6 months postoperatively. Secondary outcomes include inflammatory cytokine levels, symptom scores, endoscopic findings, polyp recurrence rates, and safety measures.
Eligibility criteria
Qualifiers
Aged 18-65 years
Diagnosed with CRSwNP according to EPOS criteria
Blood eosinophil count > 0.3 × 10⁹/L
Disqualifiers
Pregnant or lactating women.
Cystic fibrosis
primary ciliary dyskinesia
fungal ball rhinosinusitis
Trial design
Treatments tested in this trial
- Nasopharyngeal Lymphoid Tissue Ablation
- Full-House Endoscopic Sinus Surgery